A Phase 1 interventional study of Frespaciguat and Placebo in Pulmonary Arterial Hypertension, sponsored by Merck Sharp & Dohme LLC. Completed at 1 site in Moldova, Republic of. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-06-04.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Pulmonary Arterial Hypertension by Merck & Co., Inc — 3 open to participants now, 5 under way, 1 of them phase 3. Pulmonary Arterial Hypertension · Merck & Co., Inc.
Among the 17 studies in Pulmonary Arterial Hypertension by Merck & Co., Inc, this one is the 12th largest by enrollment, is one of 2 that started in 2019, is one of 4 in phase 1, and was the 6th registered.
700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.
Browse Pulmonary Arterial Hypertension studies →3 of the 17 studies in Pulmonary Arterial Hypertension by Merck & Co., Inc are open now, in 12 countries. Recruiting first, the newest first:
Merck Sharp & Dohme LLC · Sites in India
Ages 18+
Merck Sharp & Dohme LLC · Sites in Japan
Ages 1–17
Merck Sharp & Dohme LLC · Sites in United States, Australia, Colombia and 9 more countries
Ages 1–17
By country, each count listing its studies:
Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 7 · Phase 3 6 · Phase 4 1
First in 2013; this study’s year is marked. 2 started in 2019.
This study's enrollment of 25 is below the median of 40 across 478 interventional studies indexed under Pulmonary Arterial Hypertension.
Median enrollment 46 across the 17 interventional studies. Of the 12 that completed or were terminated, 11 (92%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 17 studies in Pulmonary Arterial Hypertension by Merck & Co., Inc, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study of frespaciguat in participants with Group 1 pulmonary arterial hypertension (PAH) will assess the safety, tolerability and pharmacokinetics (PK) of inhaled frespaciguat. There is no formal hypothesis to be tested.
In Part 1, one panel (Panel A) of up to 8 participants will dose in up to 3 dosing periods, with a minimum washout of 7 days between dosing periods. In each dosing period, 6 participants will receive frespaciguat and 2 will receive placebo, with 2 different participants receiving placebo in each of the dosing periods. Review of available safety data will occur prior to escalating to the next dose level.
Participants from Part 1 may continue into Part 2, which will assess safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single-dose inhaled frespaciguat. Three additional panels of participants (Panels B, C and D) will be enrolled into Part 2. Participants in Panel A will participate in 2 open-label dosing periods to assess PD measures associated with right heart catherization (RHC) [Period 2] and functional respiratory imaging (FRI) [Period 3]. Participants in Panels B, C, and D will participate in 3 dosing periods: Period 1 (open-label assessment of safety/tolerability and PK), Period 2 (FRI period) and Period 3 (RHC period).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in Panel A will receive a single inhaled dose of frespaciguat 120 ug in Period 1 of Part 1, followed by frespaciguat 165 ug in Period 2, followed by frespaciguat 240 ug in Period 3. Each dose will be separated by at least a 7-day washout. In Part 2 Period 2, participants will receive a single inhaled dose of frespaciguat 240 ug and undergo a right heart catheterization (RHC). In Part 2 Period 3, participants will receive a single inhaled dose of frespaciguat 240 ug and undergo a functional respiratory imaging (FRI).
Drug: Frespaciguat
Participants in Panel B will receive a single inhaled dose of frespaciguat 300 ug in Period 1 of Part 2. In Period 2 of Part 2, participants will receive a single inhaled dose of frespaciguat 360 ug and undergo FRI. In Period 3 of Part 2, participants receive a single inhaled dose of frespaciguat 360 ug and undergo RHC. Each dose will be separated by at least a 7-day washout.
Drug: Frespaciguat
Participants in Panel C will receive a single inhaled dose of frespaciguat 300 ug in Period 1 of Part 2. In Period 2 of Part 2, participants will receive a single inhaled dose of frespaciguat 360 ug and undergo FRI. In Period 3 of Part 2, participants receive a single inhaled dose of frespaciguat 360 ug and undergo RHC. Each dose will be separated by at least a 7-day washout.
Drug: Frespaciguat
Participants in Panel D will receive a single inhaled dose of frespaciguat 480 ug in Period 1 of Part 2. In Period 2 of Part 2, participants will receive a single inhaled dose of frespaciguat 120 ug and undergo FRI. In Period 3 of Part 2, participants receive a single inhaled dose of frespaciguat 120 ug and undergo RHC. Each dose will be separated by at least a 7-day washout.
Drug: Frespaciguat
Participants will receive a single inhaled dose of matching placebo in Part 1.
Drug: Placebo
Single inhaled dose of frespaciguat 120, 165, 240, 300, 360, or 480 ug depending upon randomization
Also known as: MK-5475
Single inhaled dose of placebo to match frespaciguat
Number of Participants Who Experienced at Least 1 Adverse Event (AE): All Parts
An AE was defined as any untoward medical occurrence in a participant which may not necessarily have a causal relationship with the treatment. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease that was temporally associated with use of a medicinal product, regardless of whether or not it was considered related to the medicinal product. The number of participants who experienced at least 1 AE was reported by dose separately for Part 1 plus Part 2 Period 1, for the RHC Period, and for the FRI Period.
Time frame: Up to ~14 days after last dose of treatment period (Up to ~32 weeks total)
Number of Participants Who Discontinued From the Study Due to an AE: All Parts
An AE was defined as any untoward medical occurrence in a participant which may not necessarily have a causal relationship with the treatment. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease that was temporally associated with use of a medicinal product, regardless of whether or not it was considered related to the medicinal product. The number of participants who discontinued from the study due to an AE was reported by dose separately for Part 1 plus Part 2 Period 1, for the RHC Period, and for the FRI Period.
Time frame: Up to ~14 days after last dose of treatment period (Up to ~32 weeks total)
Percentage Change From Baseline in Minimum Pulmonary Vascular Resistance (PVR): Part 2 Right Heart Catheterization (RHC) Period
For each participant in the RHC Period, the percentage change from baseline for the minimum post-dose PVR value over the duration of the RHC procedure was calculated. The average of pre-dose measurements was set as the baseline. Mean (SD) percent change from baseline in PVR minimum were calculated and reported for each dose group that underwent RHC in Part 2. Per protocol, this outcome measure was only assessed during the Part 2 RHC Period for each panel and was not assessed during Part 1.
Time frame: Baseline: Pre-dose on Day 1 of RHC Period (up to 185 days) and up to 4.5 hours post-dose
Change From Baseline in Heart Rate (HR) at 0.5 Hours Post-dose: Part 2 RHC Period
HR was assessed at pre-dose in the RHC Period (baseline) and at 0.5 hours post-dose. Baseline HR and change from baseline in HR was reported for each panel/dose group that underwent RHC in Part 2, according to treatment planned. Negative values indicate decreases from baseline in HR. Per protocol, this outcome measure was only assessed during the Part 2 RHC Period for each panel and was not assessed during Part 1.
Time frame: Baseline: Pre-dose on Day 1 of RHC Period (up to 185 days) and 0.5 hours post-dose
Change From Baseline in Heart Rate (HR) at 4.5 Hours Post-dose: Part 2 RHC Period
HR was assessed at pre-dose in the RHC Period (baseline) and at 4.5 hours post-dose. Baseline HR and change from baseline in HR was reported for each panel/dose group that underwent RHC in Part 2, according to treatment planned. Negative values indicate decreases from baseline in HR. Per protocol, this outcome measure was only assessed during the Part 2 RHC Period for each panel and was not assessed during Part 1.
Time frame: Baseline: Pre-dose on Day 1 of RHC Period (up to 185 days) and 4.5 hours post-dose
Change From Baseline in Heart Rate (HR) at 24 Hours Post-dose: Part 2 RHC Period
HR was assessed at pre-dose in the RHC Period (baseline) and at 24 hours post-dose. Baseline HR and change from baseline in HR was reported for each panel/dose group that underwent RHC in Part 2, according to treatment planned. Negative values indicate decreases from baseline in HR. Per protocol, this outcome measure was only assessed during the Part 2 RHC Period for each panel and was not assessed during Part 1.
Time frame: Baseline: Pre-dose on Day 1 of RHC Period (up to 185 days) and 24 hours post-dose
Change From Baseline in Systolic Blood Pressure (SBP) at 0.5 Hours Post-dose: Part 2 RHC Period
SBP was assessed at pre-dose in the RHC Period (baseline) and at 0.5 hours post-dose. Baseline SBP and change from baseline in SBP was reported for each panel/dose group that underwent RHC in Part 2, according to treatment planned. Negative values indicate decreases from baseline in SBP. Per protocol, this outcome measure was only assessed during the Part 2 RHC Period for each panel and was not assessed during Part 1.
Time frame: Baseline: Pre-dose on Day 1 of RHC Period (up to 185 days) and 0.5 hours post-dose
Change From Baseline in Systolic Blood Pressure (SBP) at 4.5 Hours Post-dose: Part 2 RHC Period
SBP was assessed at pre-dose in the RHC Period (baseline) and at 4.5 hours post-dose. Baseline SBP and change from baseline in SBP was reported for each panel/dose group that underwent RHC in Part 2, according to treatment planned. Negative values indicate decreases from baseline in SBP. Per protocol, this outcome measure was only assessed during the Part 2 RHC Period for each panel and was not assessed during Part 1.
Time frame: Baseline: Pre-dose on Day 1 of RHC Period (up to 185 days) and 4.5 hours post-dose
Change From Baseline in Systolic Blood Pressure (SBP) at 24 Hours Post-dose: Part 2 RHC Period
SBP was assessed at pre-dose in the RHC Period (baseline) and at 24 hours post-dose. Baseline SBP and change from baseline in SBP was reported for each panel/dose group that underwent RHC in Part 2, according to treatment planned. Negative values indicate decreases from baseline in SBP. Per protocol, this outcome measure was only assessed during the Part 2 RHC Period for each panel and was not assessed during Part 1.
Time frame: Baseline: Pre-dose on Day 1 of RHC Period (up to 185 days) and 24 hours post-dose
Change From Baseline in Diastolic Blood Pressure (DBP) at 0.5 Hours Post-dose: Part 2 RHC Period
DBP was assessed at pre-dose in the RHC Period (baseline) and at 0.5 hours post-dose. Baseline DBP and change from baseline in DBP was reported for each panel/dose group that underwent RHC in Part 2, according to treatment planned. Negative values indicate decreases from baseline in DBP. Per protocol, this outcome measure was only assessed during the Part 2 RHC Period for each panel and was not assessed during Part 1.
Time frame: Baseline: Pre-dose on Day 1 of RHC Period (up to 185 days) and 0.5 hours post-dose
Change From Baseline in Diastolic Blood Pressure (DBP) at 4.5 Hours Post-dose: Part 2 RHC Period
DBP was assessed at pre-dose in the RHC Period (baseline) and at 4.5 hours post-dose. Baseline DBP and change from baseline in DBP was reported for each panel/dose group that underwent RHC in Part 2, according to treatment planned. Negative values indicate decreases from baseline in DBP. Per protocol, this outcome measure was only assessed during the Part 2 RHC Period for each panel and was not assessed during Part 1.
Time frame: Baseline: Pre-dose on Day 1 of RHC Period (up to 185 days) and 4.5 hours post-dose
Change From Baseline in Diastolic Blood Pressure (DBP) at 24 Hours Post-dose: Part 2 RHC Period
DBP was assessed at pre-dose in the RHC Period (baseline) and at 24 hours post-dose. Baseline DBP and change from baseline in DBP was reported for each panel/dose group that underwent RHC in Part 2, according to treatment planned. Negative values indicate decreases from baseline in DBP. Per protocol, this outcome measure was only assessed during the Part 2 RHC Period for each panel and was not assessed during Part 1.
Time frame: Baseline: Pre-dose on Day 1 of RHC Period (up to 185 days) and 24 hours post-dose
Area Under the Concentration-Time Curve From Hour 0 to Infinity (AUC0-inf) of MK-5475: All Parts
Blood samples were taken at predose and at specified time points postdose to determine the AUC0-inf of MK-5475. AUC0-inf was defined as the area under the concentration-time curve of MK-5475 from time zero to infinity. MK-5475 AUC0-inf was reported by panel/dose group. Per protocol, percent geometric coefficient of variation (%GCV) values were not reported for groups with n\<2 participants.
Time frame: Part 1 and Part 2 Period 1: Predose and 0.1, 0.25, 0.5, 1, 2, 3, 4, 8, and 24 hours post-dose; RHC Period: predose and 0.25, 0.5, 1, 2, 3, 4, and 4.5 hours; FRI Period: predose and 1, 3, 8, and 24 hours postdose (Panel D also 0.25, 0.5, 2, 4 hours)
Area Under the Concentration-Time Curve From Hour 0 to 24 Hours (AUC0-24hr) of MK-5475: All Parts
Blood samples were taken at predose and at specified time points postdose to determine the AUC0-24hr of MK-5475. AUC0-24hr was defined as the area under the concentration-time curve of MK-5475 from time zero to 24 hours. MK-5475 AUC0-24hr was reported by panel/dose group. For RHC panel/dose groups where sampling was only done up to 4.5 hours, the AUC0-24hr geometric mean represents an extrapolated AUC0-24hr value. Per protocol, %GCV values were not reported for groups with n\<2 participants.
Time frame: Part 1 and Part 2 Period 1: Predose and 0.1, 0.25, 0.5, 1, 2, 3, 4, 8, and 24 hours post-dose; RHC Period: predose and 0.25, 0.5, 1, 2, 3, 4, and 4.5 hours; FRI Period: predose and 1, 3, 8, and 24 hours postdose (Panel D also 0.25, 0.5, 2, 4 hours)
Maximum Concentration (Cmax) of MK-5475: All Parts
Blood samples were taken at predose and at specified time points postdose to determine the Cmax of MK-5475. Cmax was defined as the maximum concentration of MK-5475 reached. MK-5475 Cmax was reported by panel/dose group. Per protocol, %GCV values were not reported for groups with n\<2 participants.
Time frame: Part 1 and Part 2 Period 1: Predose and 0.1, 0.25, 0.5, 1, 2, 3, 4, 8, and 24 hours post-dose; RHC Period: predose and 0.25, 0.5, 1, 2, 3, 4, and 4.5 hours; FRI Period: predose and 1, 3, 8, and 24 hours postdose (Panel D also 0.25, 0.5, 2, 4 hours)
Concentration of MK-5475 at 24 Hours Postdose (C24): All Parts
Blood samples were taken at predose and at specified time points postdose to determine the C24 of MK-5475. C24 was defined as the concentration of MK-5475 reached at 24 hours. MK-5475 Cmax was reported by panel/dose group. Per protocol, %GCV values were not reported for groups with n\<2 participants.
Time frame: 24 hours postdose
Time to Maximum Concentration (Tmax) of MK-5475: All Parts
Blood samples were taken at predose and at specified time points postdose to determine the Tmax of MK-5475. Tmax was defined as the time to maximum concentration of MK-5475. MK-5475 Tmax was reported by panel/dose group.
Time frame: Part 1 and Part 2 Period 1: Predose and 0.1, 0.25, 0.5, 1, 2, 3, 4, 8, and 24 hours post-dose; RHC Period: predose and 0.25, 0.5, 1, 2, 3, 4, and 4.5 hours; FRI Period: predose and 1, 3, 8, and 24 hours postdose (Panel D also 0.25, 0.5, 2, 4 hours)
Apparent Terminal Half-life (t1/2) of MK-5475: All Parts
Blood samples were taken at predose and at specified time points postdose to determine the t½ of MK-5475. t½ was defined as the time required to divide the MK-5475 plasma concentration by two after reaching pseudo-equilibrium, following a single dose of MK-5475. MK-5475 t½ was reported by panel/dose group.
Time frame: Part 1 and Part 2 Period 1: Predose and 0.1, 0.25, 0.5, 1, 2, 3, 4, 8, and 24 hours post-dose; RHC Period: predose and 0.25, 0.5, 1, 2, 3, 4, and 4.5 hours; FRI Period: predose and 1, 3, 8, and 24 hours postdose (Panel D also 0.25, 0.5, 2, 4 hours)
Percentage Change From Baseline in Pulmonary Blood Volume (PBV) Over Time: Part 2 Functional Respiratory Imaging (FRI) Period
Participants underwent a series of computed tomography (CT) scans with an intravenous (IV) iodinated contrast agent to facilitate assessment of PBV at baseline and at several times points after MK-5475 dosing. Percentage change from baseline (CFB) in PBV was calculated and reported for each dose group that underwent FRI in Part 2. As pre-specified, central tendency for PBV percentage CFB was provided as numerical values rounded to whole numbers. Per protocol, this outcome measure was only assessed during the Part 2 FRI Period for each panel and was not assessed during Part 1.
Time frame: Baseline: Pre-dose on Day 1 of FRI Period (up to 227 days) and 1, 3, 8, and 24 hours post-dose
Adult participants with Group 1 Pulmonary Arterial Hypertension (PAH) were recruited to evaluate safety, pharmacokinetics (PK), Functional Respiratory Imaging (FRI), and Right Heart Catheterization (RHC) of single-dose MK-5475.
| Milestone | MK-5475 120 ug/MK-5475 165 ug/MK-5475 240 ug/MK-5475 240 ug/MK-5475 240 ug (Panel A) | MK-5475 120 ug/Placebo/MK-5475 240 ug/MK-5475 240 ug/MK-5475 240 ug (Panel A) | MK-5475 120 ug/MK-5475 165 ug/Placebo/MK-5475 240 ug/MK-5475 240 ug (Panel A) | Placebo/MK-5475 165 ug/MK-5475 240 ug/MK-5475 240 ug/MK-5475 240 ug (Panel A) | Placebo/MK-5475 165 ug/MK-5475 240 ug (Panel A) | MK-5475 300 ug/ MK-5475 165 ug/ MK-5475 165 ug (Panel B) | MK-5475 300 ug/ MK-5475 360 ug/ MK-5475 360 ug (Panels B+C) | MK-5475 300 ug/ MK-5475 120 ug/ MK-5475 120 ug (Panel C) | MK-5475 480 ug/ MK-5475 120 ug/ MK-5475 120 ug (Panel D) | MK-5475 480 ug/ MK-5475 120 ug (Panel D) |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 2 | 2 | 2 | 1 | 1 | 1 | 8 | 4 | 3 | 1 |
| Completed | 2 | 2 | 2 | 1 | 1 | 1 | 8 | 4 | 3 | 1 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
An AE was defined as any untoward medical occurrence in a participant which may not necessarily have a causal relationship with the treatment. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease that was temporally associated with use of a medicinal product, regardless of whether or not it was considered related to the medicinal product. The number of participants who experienced at least 1 AE was reported by dose separately for Part 1 plus Part 2 Period 1, for the RHC Period, and for the FRI Period.
| Participants | MK-5475 120 ug: Part 1 (Panel A) | MK-5475 165 ug: Part 1 (Panel A) | MK-5475 240 ug: Part 1 (Panel A) | MK-5475 300 ug: Part 2 Period 1 (Panels B+C) | MK-5475 480 ug: Part 2 Period 1 (Panel D) | Placebo: Part 1 | MK-5475 120 ug: RHC (Panel D) | MK-5475 165 ug: RHC (Panel B) | MK-5475 240 ug: RHC (Panel A) | MK-5475 360 ug: RHC (Panels B+C) | MK-5475 120 ug: FRI (Panels C+D) | MK-5475 165 ug: FRI (Panel B) | MK-5475 240 ug: FRI (Panel A) | MK-5475 360 ug: FRI (Panels B+C) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants Who Experienced at Least 1 Adverse Event (AE): All Parts | 2 | 1 | 3 | 5 | 2 | 4 | 5 | 1 | 6 | 4 | 1 | 0 | 0 | 4 |
An AE was defined as any untoward medical occurrence in a participant which may not necessarily have a causal relationship with the treatment. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease that was temporally associated with use of a medicinal product, regardless of whether or not it was considered related to the medicinal product. The number of participants who discontinued from the study due to an AE was reported by dose separately for Part 1 plus Part 2 Period 1, for the RHC Period, and for the FRI Period.
| Participants | MK-5475 120 ug: Part 1 (Panel A) | MK-5475 165 ug: Part 1 (Panel A) | MK-5475 240 ug: Part 1 (Panel A) | MK-5475 300 ug: Part 2 Period 1 (Panels B+C) | MK-5475 480 ug: Part 2 Period 1 (Panel D) | Placebo: Part 1 | MK-5475 120 ug: RHC (Panel D) | MK-5475 165 ug: RHC (Panel B) | MK-5475 240 ug: RHC (Panel A) | MK-5475 360 ug: RHC (Panels B+C) | MK-5475 120 ug: FRI (Panels C+D) | MK-5475 165 ug: FRI (Panel B) | MK-5475 240 ug: FRI (Panel A) | MK-5475 360 ug: FRI (Panels B+C) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants Who Discontinued From the Study Due to an AE: All Parts | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
For each participant in the RHC Period, the percentage change from baseline for the minimum post-dose PVR value over the duration of the RHC procedure was calculated. The average of pre-dose measurements was set as the baseline. Mean (SD) percent change from baseline in PVR minimum were calculated and reported for each dose group that underwent RHC in Part 2. Per protocol, this outcome measure was only assessed during the Part 2 RHC Period for each panel and was not assessed during Part 1.
| Percentage change | MK-5475 120 ug: Part 1 (Panel A) | MK-5475 165 ug: Part 1 (Panel A) | MK-5475 240 ug: Part 1 (Panel A) | MK-5475 300 ug: Part 2 Period 1 (Panels B+C) | MK-5475 480 ug: Part 2 Period 1 (Panel D) | Placebo: Part 1 | MK-5475 120 ug: RHC (Panel D) | MK-5475 165 ug: RHC (Panel B) | MK-5475 240 ug: RHC (Panel A) | MK-5475 360 ug: RHC (Panels B+C) | MK-5475 120 ug: FRI (Panels C+D) | MK-5475 165 ug: FRI (Panel B) | MK-5475 240 ug: FRI (Panel A) | MK-5475 360 ug: FRI (Panels B+C) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Percentage Change From Baseline in Minimum Pulmonary Vascular Resistance (PVR): Part 2 Right Heart Catheterization (RHC) Period | — | — | — | — | — | — | -20.77 ± 13.88 | 13.01 ± NA | -29.46 ± 13.72 | -29.25 ± 17.58 | — | — | — | — |
HR was assessed at pre-dose in the RHC Period (baseline) and at 0.5 hours post-dose. Baseline HR and change from baseline in HR was reported for each panel/dose group that underwent RHC in Part 2, according to treatment planned. Negative values indicate decreases from baseline in HR. Per protocol, this outcome measure was only assessed during the Part 2 RHC Period for each panel and was not assessed during Part 1.
| beats/minute | MK-5475 120 ug: Part 1 | MK-5475 165 ug: Part 1 | MK-5475 240 ug: Part 1 | MK-5475 300 ug: Part 2 Period 1 | MK-5475 480 ug: Part 2 Period 1 | Placebo: Part 1 | MK-5475 120 ug: RHC (Panel D) | MK-5475 165 ug: RHC (Panel B) | MK-5475 240 ug: RHC (Panel A) | MK-5475 360 ug: RHC (Panel B) | MK-5475 360 ug: RHC (Panel C) | MK-5475 120 ug: FRI | MK-5475 165 ug: FRI (Panel B) | MK-5475 240 ug: FRI | MK-5475 360 ug: FRI |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline HR | — | — | — | — | — | — | 74.75 ± 9.78 | — | 62.57 ± 6.23 | 68.75 ± 2.36 | 69.06 ± 4.29 | — | — | — | — |
| Change from Baseline in HR | — | — | — | — | — | — | 3.56 ± 7.60 | — | 1.83 ± 1.56 | 4.92 ± 3.03 | -2.76 ± 1.60 | — | — | — | — |
HR was assessed at pre-dose in the RHC Period (baseline) and at 4.5 hours post-dose. Baseline HR and change from baseline in HR was reported for each panel/dose group that underwent RHC in Part 2, according to treatment planned. Negative values indicate decreases from baseline in HR. Per protocol, this outcome measure was only assessed during the Part 2 RHC Period for each panel and was not assessed during Part 1.
| beats/minute | MK-5475 120 ug: Part 1 | MK-5475 165 ug: Part 1 | MK-5475 240 ug: Part 1 | MK-5475 300 ug: Part 2 Period 1 | MK-5475 480 ug: Part 2 Period 1 | Placebo: Part 1 | MK-5475 120 ug: RHC (Panel D) | MK-5475 165 ug: RHC (Panel B) | MK-5475 240 ug: RHC (Panel A) | MK-5475 360 ug: RHC (Panel B) | MK-5475 360 ug: RHC (Panel C) | MK-5475 120 ug: FRI | MK-5475 165 ug: FRI (Panel B) | MK-5475 240 ug: FRI | MK-5475 360 ug: FRI |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline HR | — | — | — | — | — | — | 74.75 ± 9.78 | — | 62.57 ± 6.23 | 68.75 ± 2.36 | 69.06 ± 4.29 | — | — | — | — |
| Change from Baseline in HR | — | — | — | — | — | — | -0.56 ± 4.55 | — | 3.20 ± 3.51 | 7.17 ± 1.55 | -0.98 ± 2.01 | — | — | — | — |
HR was assessed at pre-dose in the RHC Period (baseline) and at 24 hours post-dose. Baseline HR and change from baseline in HR was reported for each panel/dose group that underwent RHC in Part 2, according to treatment planned. Negative values indicate decreases from baseline in HR. Per protocol, this outcome measure was only assessed during the Part 2 RHC Period for each panel and was not assessed during Part 1.
| beats/minute | MK-5475 120 ug: Part 1 | MK-5475 165 ug: Part 1 | MK-5475 240 ug: Part 1 | MK-5475 300 ug: Part 2 Period 1 | MK-5475 480 ug: Part 2 Period 1 | Placebo: Part 1 | MK-5475 120 ug: RHC (Panel D) | MK-5475 165 ug: RHC (Panel B) | MK-5475 240 ug: RHC (Panel A) | MK-5475 360 ug: RHC (Panel B) | MK-5475 360 ug: RHC (Panel C) | MK-5475 120 ug: FRI | MK-5475 165 ug: FRI (Panel B) | MK-5475 240 ug: FRI | MK-5475 360 ug: FRI |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline HR | — | — | — | — | — | — | 74.75 ± 9.78 | — | 62.57 ± 6.23 | 68.75 ± 2.36 | 69.06 ± 4.29 | — | — | — | — |
| Change from Baseline in HR | — | — | — | — | — | — | 1.78 ± 7.35 | — | 7.43 ± 3.32 | 2.42 ± 3.10 | -0.72 ± 2.53 | — | — | — | — |
SBP was assessed at pre-dose in the RHC Period (baseline) and at 0.5 hours post-dose. Baseline SBP and change from baseline in SBP was reported for each panel/dose group that underwent RHC in Part 2, according to treatment planned. Negative values indicate decreases from baseline in SBP. Per protocol, this outcome measure was only assessed during the Part 2 RHC Period for each panel and was not assessed during Part 1.
| Millimeters of mercury (mmHg) | MK-5475 120 ug: Part 1 | MK-5475 165 ug: Part 1 | MK-5475 240 ug: Part 1 | MK-5475 300 ug: Part 2 Period 1 | MK-5475 480 ug: Part 2 Period 1 | Placebo: Part 1 | MK-5475 120 ug: RHC (Panel D) | MK-5475 165 ug: RHC (Panel B) | MK-5475 240 ug: RHC (Panel A) | MK-5475 360 ug: RHC (Panel B) | MK-5475 360 ug: RHC (Panel C) | MK-5475 120 ug: FRI | MK-5475 165 ug: FRI (Panel B) | MK-5475 240 ug: FRI | MK-5475 360 ug: FRI |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline SBP | — | — | — | — | — | — | 123.25 ± 9.80 | — | 132.86 ± 3.79 | 128.50 ± 9.65 | 119.11 ± 4.72 | — | — | — | — |
| Change from Baseline in SBP | — | — | — | — | — | — | 25.33 ± 2.52 | — | 2.67 ± 3.70 | -1.17 ± 3.46 | 5.30 ± 2.36 | — | — | — | — |
SBP was assessed at pre-dose in the RHC Period (baseline) and at 4.5 hours post-dose. Baseline SBP and change from baseline in SBP was reported for each panel/dose group that underwent RHC in Part 2, according to treatment planned. Negative values indicate decreases from baseline in SBP. Per protocol, this outcome measure was only assessed during the Part 2 RHC Period for each panel and was not assessed during Part 1.
| Millimeters of mercury (mmHg) | MK-5475 120 ug: Part 1 | MK-5475 165 ug: Part 1 | MK-5475 240 ug: Part 1 | MK-5475 300 ug: Part 2 Period 1 | MK-5475 480 ug: Part 2 Period 1 | Placebo: Part 1 | MK-5475 120 ug: RHC (Panel D) | MK-5475 165 ug: RHC (Panel B) | MK-5475 240 ug: RHC (Panel A) | MK-5475 360 ug: RHC (Panel B) | MK-5475 360 ug: RHC (Panel C) | MK-5475 120 ug: FRI | MK-5475 165 ug: FRI (Panel B) | MK-5475 240 ug: FRI | MK-5475 360 ug: FRI |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline SBP | — | — | — | — | — | — | 123.25 ± 9.80 | — | 132.86 ± 3.79 | 128.50 ± 9.65 | 119.11 ± 4.72 | — | — | — | — |
| Change from Baseline in SBP | — | — | — | — | — | — | 10.67 ± 0.38 | — | 4.93 ± 5.65 | 7.50 ± 1.55 | 11.96 ± 6.31 | — | — | — | — |
SBP was assessed at pre-dose in the RHC Period (baseline) and at 24 hours post-dose. Baseline SBP and change from baseline in SBP was reported for each panel/dose group that underwent RHC in Part 2, according to treatment planned. Negative values indicate decreases from baseline in SBP. Per protocol, this outcome measure was only assessed during the Part 2 RHC Period for each panel and was not assessed during Part 1.
| Millimeters of mercury (mmHg) | MK-5475 120 ug: Part 1 | MK-5475 165 ug: Part 1 | MK-5475 240 ug: Part 1 | MK-5475 300 ug: Part 2 Period 1 | MK-5475 480 ug: Part 2 Period 1 | Placebo: Part 1 | MK-5475 120 ug: RHC (Panel D) | MK-5475 165 ug: RHC (Panel B) | MK-5475 240 ug: RHC (Panel A) | MK-5475 360 ug: RHC (Panel B) | MK-5475 360 ug: RHC (Panel C) | MK-5475 120 ug: FRI | MK-5475 165 ug: FRI (Panel B) | MK-5475 240 ug: FRI | MK-5475 360 ug: FRI |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline SBP | — | — | — | — | — | — | 123.25 ± 9.80 | — | 132.86 ± 3.79 | 128.50 ± 9.65 | 119.11 ± 4.72 | — | — | — | — |
| Change from Baseline in SBP | — | — | — | — | — | — | 6.22 ± 5.28 | — | -5.95 ± 5.78 | 2.25 ± 7.62 | 0.74 ± 3.44 | — | — | — | — |
DBP was assessed at pre-dose in the RHC Period (baseline) and at 0.5 hours post-dose. Baseline DBP and change from baseline in DBP was reported for each panel/dose group that underwent RHC in Part 2, according to treatment planned. Negative values indicate decreases from baseline in DBP. Per protocol, this outcome measure was only assessed during the Part 2 RHC Period for each panel and was not assessed during Part 1.
| Millimeters of mercury (mmHg) | MK-5475 120 ug: Part 1 | MK-5475 165 ug: Part 1 | MK-5475 240 ug: Part 1 | MK-5475 300 ug: Part 2 Period 1 | MK-5475 480 ug: Part 2 Period 1 | Placebo: Part 1 | MK-5475 120 ug: RHC (Panel D) | MK-5475 165 ug: RHC (Panel B) | MK-5475 240 ug: RHC (Panel A) | MK-5475 360 ug: RHC (Panel B) | MK-5475 360 ug: RHC (Panel C) | MK-5475 120 ug: FRI | MK-5475 165 ug: FRI (Panel B) | MK-5475 240 ug: FRI | MK-5475 360 ug: FRI |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline DBP | — | — | — | — | — | — | 69.75 ± 4.03 | — | 72.43 ± 2.25 | 77.00 ± 4.95 | 70.78 ± 3.52 | — | — | — | — |
| Change from Baseline in DBP | — | — | — | — | — | — | 4.00 ± 4.60 | — | 0.94 ± 1.68 | 0.75 ± 3.48 | 1.30 ± 1.75 | — | — | — | — |
DBP was assessed at pre-dose in the RHC Period (baseline) and at 4.5 hours post-dose. Baseline DBP and change from baseline in DBP was reported for each panel/dose group that underwent RHC in Part 2, according to treatment planned. Negative values indicate decreases from baseline in DBP. Per protocol, this outcome measure was only assessed during the Part 2 RHC Period for each panel and was not assessed during Part 1.
| Millimeters of mercury (mmHg) | MK-5475 120 ug: Part 1 | MK-5475 165 ug: Part 1 | MK-5475 240 ug: Part 1 | MK-5475 300 ug: Part 2 Period 1 | MK-5475 480 ug: Part 2 Period 1 | Placebo: Part 1 | MK-5475 120 ug: RHC (Panel D) | MK-5475 165 ug: RHC (Panel B) | MK-5475 240 ug: RHC (Panel A) | MK-5475 360 ug: RHC (Panel B) | MK-5475 360 ug: RHC (Panel C) | MK-5475 120 ug: FRI | MK-5475 165 ug: FRI (Panel B) | MK-5475 240 ug: FRI | MK-5475 360 ug: FRI |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline DBP | — | — | — | — | — | — | 69.75 ± 4.03 | — | 72.43 ± 2.25 | 77.00 ± 4.95 | 70.78 ± 3.52 | — | — | — | — |
| Change from Baseline in DBP | — | — | — | — | — | — | -0.22 ± 4.87 | — | 1.07 ± 2.34 | 3.58 ± 2.73 | 4.00 ± 4.28 | — | — | — | — |
DBP was assessed at pre-dose in the RHC Period (baseline) and at 24 hours post-dose. Baseline DBP and change from baseline in DBP was reported for each panel/dose group that underwent RHC in Part 2, according to treatment planned. Negative values indicate decreases from baseline in DBP. Per protocol, this outcome measure was only assessed during the Part 2 RHC Period for each panel and was not assessed during Part 1.
| Millimeters of mercury (mmHg) | MK-5475 120 ug: Part 1 | MK-5475 165 ug: Part 1 | MK-5475 240 ug: Part 1 | MK-5475 300 ug: Part 2 Period 1 | MK-5475 480 ug: Part 2 Period 1 | Placebo: Part 1 | MK-5475 120 ug: RHC (Panel D) | MK-5475 165 ug: RHC (Panel B) | MK-5475 240 ug: RHC (Panel A) | MK-5475 360 ug: RHC (Panel B) | MK-5475 360 ug: RHC (Panel C) | MK-5475 120 ug: FRI | MK-5475 165 ug: FRI (Panel B) | MK-5475 240 ug: FRI | MK-5475 360 ug: FRI |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline SBP | — | — | — | — | — | — | 69.75 ± 4.03 | — | 72.43 ± 2.25 | 77.00 ± 4.95 | 70.78 ± 3.52 | — | — | — | — |
| Change from Baseline in SBP | — | — | — | — | — | — | -1.44 ± 0.89 | — | -2.76 ± 3.22 | 2.42 ± 3.15 | -1.74 ± 2.89 | — | — | — | — |
Blood samples were taken at predose and at specified time points postdose to determine the AUC0-inf of MK-5475. AUC0-inf was defined as the area under the concentration-time curve of MK-5475 from time zero to infinity. MK-5475 AUC0-inf was reported by panel/dose group. Per protocol, percent geometric coefficient of variation (%GCV) values were not reported for groups with n\<2 participants.
| nM*hr | MK-5475 120 ug: Part 1 (Panel A) | MK-5475 165 ug: Part 1 (Panel A) | MK-5475 240 ug: Part 1 (Panel A) | MK-5475 300 ug: Part 2 Period 1 (Panel B) | MK-5475 300 ug: Part 2 Period 1 (Panel C) | MK-5475 480 ug: Part 2 Period 1 (Panel D) | Placebo: Part 1 | MK-5475 120 ug: RHC (Panel C) | MK-5475 120 ug: RHC (Panel D) | MK-5475 165 ug: RHC (Panel B) | MK-5475 240 ug: RHC (Panel A) | MK-5475 360 ug: RHC (Panel B) | MK-5475 360 ug: RHC (Panel C) | MK-5475 120 ug: FRI (Panel C) | MK-5475 120 ug: FRI (Panel D) | MK-5475 165 ug: FRI (Panel B) | MK-5475 240 ug: FRI (Panel A) | MK-5475 360 ug: FRI (Panel B) | MK-5475 360 ug: FRI (Panel C) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Area Under the Concentration-Time Curve From Hour 0 to Infinity (AUC0-inf) of MK-5475: All Parts | 1.00 ± 45.5 | 0.721 ± 103.6 | 1.25 ± 59.7 | 2.15 ± 106.3 | 1.66 ± 66.8 | 4.59 ± 20.9 | — | 1.03 ± 20.0 | 1.05 ± 28.9 | — | 1.03 ± 59.7 | 1.46 ± 63.2 | 3.46 ± 67.3 | 0.748 ± 43.9 | 0.978 ± 18.3 | 4.26 ± NA | — | — | 4.10 ± 37.6 |
Blood samples were taken at predose and at specified time points postdose to determine the AUC0-24hr of MK-5475. AUC0-24hr was defined as the area under the concentration-time curve of MK-5475 from time zero to 24 hours. MK-5475 AUC0-24hr was reported by panel/dose group. For RHC panel/dose groups where sampling was only done up to 4.5 hours, the AUC0-24hr geometric mean represents an extrapolated AUC0-24hr value. Per protocol, %GCV values were not reported for groups with n\<2 participants.
| nM*hr | MK-5475 120 ug: Part 1 (Panel A) | MK-5475 165 ug: Part 1 (Panel A) | MK-5475 240 ug: Part 1 (Panel A) | MK-5475 300 ug: Part 2 Period 1 (Panel B) | MK-5475 300 ug: Part 2 Period 1 (Panel C) | MK-5475 480 ug: Part 2 Period 1 (Panel D) | Placebo: Part 1 | MK-5475 120 ug: RHC (Panel C) | MK-5475 120 ug: RHC (Panel D) | MK-5475 165 ug: RHC (Panel B) | MK-5475 240 ug: RHC (Panel A) | MK-5475 360 ug: RHC (Panel B) | MK-5475 360 ug: RHC (Panel C) | MK-5475 120 ug: FRI (Panel C) | MK-5475 120 ug: FRI (Panel D) | MK-5475 165 ug: FRI (Panel B) | MK-5475 240 ug: FRI (Panel A) | MK-5475 360 ug: FRI (Panel B) | MK-5475 360 ug: FRI (Panel C) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Area Under the Concentration-Time Curve From Hour 0 to 24 Hours (AUC0-24hr) of MK-5475: All Parts | 0.259 ± 288.2 | 0.613 ± 136.0 | 1.42 ± 59.9 | 2.35 ± 96.2 | 1.82 ± 63.2 | 4.53 ± 21.0 | — | 1.02 ± 18.5 | 1.05 ± 28.9 | NA ± NA | 1.04 ± 59.0 | 1.45 ± 61.7 | 3.48 ± 68.3 | 0.747 ± 43.5 | 1.13 ± 18.4 | 4.19 ± NA | 1.71 ± 43.3 | 1.21 ± 80.1 | 3.82 ± 35.3 |
Blood samples were taken at predose and at specified time points postdose to determine the Cmax of MK-5475. Cmax was defined as the maximum concentration of MK-5475 reached. MK-5475 Cmax was reported by panel/dose group. Per protocol, %GCV values were not reported for groups with n\<2 participants.
| nM | MK-5475 120 ug: Part 1 (Panel A) | MK-5475 165 ug: Part 1 (Panel A) | MK-5475 240 ug: Part 1 (Panel A) | MK-5475 300 ug: Part 2 Period 1 (Panel B) | MK-5475 300 ug: Part 2 Period 1 (Panel C) | MK-5475 480 ug: Part 2 Period 1 (Panel D) | Placebo: Part 1 | MK-5475 120 ug: RHC (Panel C) | MK-5475 120 ug: RHC (Panel D) | MK-5475 165 ug: RHC (Panel B) | MK-5475 240 ug: RHC (Panel A) | MK-5475 360 ug: RHC (Panel B) | MK-5475 360 ug: RHC (Panel C) | MK-5475 120 ug: FRI (Panel C) | MK-5475 120 ug: FRI (Panel D) | MK-5475 165 ug: FRI (Panel B) | MK-5475 240 ug: FRI (Panel A) | MK-5475 360 ug: FRI (Panel B) | MK-5475 360 ug: FRI (Panel C) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Maximum Concentration (Cmax) of MK-5475: All Parts | 0.0722 ± 153.3 | 0.139 ± 117.9 | 0.297 ± 60.8 | 0.543 ± 73.9 | 0.409 ± 66.0 | 0.981 ± 22.9 | — | 0.218 ± 4.7 | 0.161 ± 76.5 | 0.312 ± NA | 0.202 ± 59.7 | 0.307 ± 21.7 | 0.960 ± 67.9 | 0.228 ± 36.8 | 0.245 ± 21.7 | 0.601 ± NA | 0.341 ± 40.1 | 0.301 ± 69.8 | 0.915 ± 56.5 |
Blood samples were taken at predose and at specified time points postdose to determine the C24 of MK-5475. C24 was defined as the concentration of MK-5475 reached at 24 hours. MK-5475 Cmax was reported by panel/dose group. Per protocol, %GCV values were not reported for groups with n\<2 participants.
| nM | MK-5475 120 ug: Part 1 (Panel A) | MK-5475 165 ug: Part 1 (Panel A) | MK-5475 240 ug: Part 1 (Panel A) | MK-5475 300 ug: Part 2 Period 1 (Panel B) | MK-5475 300 ug: Part 2 Period 1 (Panel C) | MK-5475 480 ug: Part 2 Period 1 (Panel D) | Placebo: Part 1 | MK-5475 120 ug: RHC (Panel C) | MK-5475 120 ug: RHC (Panel D) | MK-5475 165 ug: RHC (Panel B) | MK-5475 240 ug: RHC (Panel A) | MK-5475 360 ug: RHC (Panel B) | MK-5475 360 ug: RHC (Panel C) | MK-5475 120 ug: FRI (Panel C) | MK-5475 120 ug: FRI (Panel D) | MK-5475 165 ug: FRI (Panel B) | MK-5475 240 ug: FRI (Panel A) | MK-5475 360 ug: FRI (Panel B) | MK-5475 360 ug: FRI (Panel C) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Concentration of MK-5475 at 24 Hours Postdose (C24): All Parts | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | 0.0113 ± 25.0 | — | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | 0.0128 ± NA | NA ± NA | NA ± NA | NA ± NA |
Blood samples were taken at predose and at specified time points postdose to determine the Tmax of MK-5475. Tmax was defined as the time to maximum concentration of MK-5475. MK-5475 Tmax was reported by panel/dose group.
| Hour | MK-5475 120 ug: Part 1 (Panel A) | MK-5475 165 ug: Part 1 (Panel A) | MK-5475 240 ug: Part 1 (Panel A) | MK-5475 300 ug: Part 2 Period 1 (Panel B) | MK-5475 300 ug: Part 2 Period 1 (Panel C) | MK-5475 480 ug: Part 2 Period 1 (Panel D) | Placebo: Part 1 | MK-5475 120 ug: RHC (Panel C) | MK-5475 120 ug: RHC (Panel D) | MK-5475 165 ug: RHC (Panel B) | MK-5475 240 ug: RHC (Panel A) | MK-5475 360 ug: RHC (Panel B) | MK-5475 360 ug: RHC (Panel C) | MK-5475 120 ug: FRI (Panel C) | MK-5475 120 ug: FRI (Panel D) | MK-5475 165 ug: FRI (Panel B) | MK-5475 240 ug: FRI (Panel A) | MK-5475 360 ug: FRI (Panel B) | MK-5475 360 ug: FRI (Panel C) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Time to Maximum Concentration (Tmax) of MK-5475: All Parts | 2.00 (2.00 to 2.00) | 1.00 (1.00 to 2.00) | 2.00 (1.00 to 2.00) | 1.50 (1.00 to 2.00) | 1.00 (1.00 to 2.00) | 1.00 (1.00 to 2.00) | — | 1.00 (0.50 to 1.00) | 1.00 (0.00 to 1.00) | 3.00 (3.00 to 3.00) | 2.00 (1.00 to 3.00) | 1.00 (1.00 to 1.00) | 1.00 (0.50 to 1.00) | 1.00 (1.00 to 3.00) | 1.50 (1.00 to 2.00) | 1.00 (1.00 to 1.00) | 1.00 (1.00 to 3.00) | 1.00 (1.00 to 3.00) | 1.00 (1.00 to 1.00) |
Blood samples were taken at predose and at specified time points postdose to determine the t½ of MK-5475. t½ was defined as the time required to divide the MK-5475 plasma concentration by two after reaching pseudo-equilibrium, following a single dose of MK-5475. MK-5475 t½ was reported by panel/dose group.
| Hour | MK-5475 120 ug: Part 1 (Panel A) | MK-5475 165 ug: Part 1 (Panel A) | MK-5475 240 ug: Part 1 (Panel A) | MK-5475 300 ug: Part 2 Period 1 (Panel B) | MK-5475 300 ug: Part 2 Period 1 (Panel C) | MK-5475 480 ug: Part 2 Period 1 (Panel D) | Placebo: Part 1 | MK-5475 120 ug: RHC (Panel C) | MK-5475 120 ug: RHC (Panel D) | MK-5475 165 ug: RHC (Panel B) | MK-5475 240 ug: RHC (Panel A) | MK-5475 360 ug: RHC (Panel B) | MK-5475 360 ug: RHC (Panel C) | MK-5475 120 ug: FRI (Panel C) | MK-5475 120 ug: FRI (Panel D) | MK-5475 165 ug: FRI (Panel B) | MK-5475 240 ug: FRI (Panel A) | MK-5475 360 ug: FRI (Panel B) | MK-5475 360 ug: FRI (Panel C) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apparent Terminal Half-life (t1/2) of MK-5475: All Parts | 1.73 ± 11.4 | 1.76 ± 10.9 | 1.87 ± 13.5 | 2.12 ± 37.2 | 2.18 ± 37.9 | 3.67 ± 6.6 | — | 2.82 ± 10.5 | 2.32 ± 21.0 | — | 2.35 ± 9.2 | 3.13 ± 45.5 | 2.05 ± 11.6 | 2.45 ± 24.6 | 2.19 ± 8.1 | 3.89 ± NA | — | — | 3.92 ± 7.9 |
Participants underwent a series of computed tomography (CT) scans with an intravenous (IV) iodinated contrast agent to facilitate assessment of PBV at baseline and at several times points after MK-5475 dosing. Percentage change from baseline (CFB) in PBV was calculated and reported for each dose group that underwent FRI in Part 2. As pre-specified, central tendency for PBV percentage CFB was provided as numerical values rounded to whole numbers. Per protocol, this outcome measure was only assessed during the Part 2 FRI Period for each panel and was not assessed during Part 1.
| Percentage change | MK-5475 120 ug: Part 1 (Panel A) | MK-5475 165 ug: Part 1 (Panel A) | MK-5475 240 ug: Part 1 (Panel A) | MK-5475 300 ug: Part 2 Period 1 (Panels B+C) | MK-5475 480 ug: Part 2 Period 1 (Panel D) | Placebo: Part 1 | MK-5475 120 ug: RHC (Panel D) | MK-5475 165 ug: RHC (Panel B) | MK-5475 240 ug: RHC (Panel A) | MK-5475 360 ug: RHC (Panels B+C) | MK-5475 120 ug: FRI (Panels C+D) | MK-5475 165 ug: FRI (Panel B) | MK-5475 240 ug: FRI (Panel A) | MK-5475 360 ug: FRI (Panels B+C) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CFB at 1 hour | — | — | — | — | — | — | — | — | — | — | -2 | — | 2 | 3 |
| CFB at 3 hours | — | — | — | — | — | — | — | — | — | — | 2 | — | 2 | 9 |
| CFB at 8 hours | — | — | — | — | — | — | — | — | — | — | 3 | — | 11 | 9 |
| CFB at 24 hours | — | — | — | — | — | — | — | — | — | — | -2 | — | 3 | 6 |
Collected over Up to ~14 days after last dose of treatment period (Up to ~32 weeks total). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| MK-5475 120 ug: Part 1 (Panel A) | 0/6 (0%) | 0/6 (0%) | 2/6 (33.3%) |
| MK-5475 165 ug: Part 1 (Panel A) | 0/6 (0%) | 0/6 (0%) | 1/6 (16.7%) |
| MK-5475 240 ug: Part 1 (Panel A) | 0/6 (0%) | 0/6 (0%) | 3/6 (50%) |
| MK-5475 300 ug: Part 2 Period 1 (Panels B+C) | 0/13 (0%) | 0/13 (0%) | 5/13 (38.5%) |
| MK-5475 480 ug: Part 2 Period 1 (Panel D) | 0/4 (0%) | 0/4 (0%) | 2/4 (50%) |
| Placebo: Part 1 | 0/6 (0%) | 0/6 (0%) | 4/6 (66.7%) |
| MK-5475 120 ug: RHC (Panel D) | 0/7 (0%) | 0/7 (0%) | 5/7 (71.4%) |
| MK-5475 165 ug: RHC (Panel B) | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) |
| MK-5475 240 ug: RHC (Panel A) | 0/7 (0%) | 0/7 (0%) | 6/7 (85.7%) |
| MK-5475 360 ug: RHC (Panels B+C) | 0/8 (0%) | 0/8 (0%) | 4/8 (50%) |
| MK-5475 120 ug: FRI (Panels C+D) | 0/8 (0%) | 0/8 (0%) | 1/8 (12.5%) |
| MK-5475 165 ug: FRI (Panel B) | 0/1 (0%) | 0/1 (0%) | 0/1 (0%) |
| MK-5475 240 ug: FRI (Panel A) | 0/7 (0%) | 0/7 (0%) | 0/7 (0%) |
| MK-5475 360 ug: FRI (Panels B+C) | 0/8 (0%) | 0/8 (0%) | 4/8 (50%) |
| Event | MK-5475 120 ug: Part 1 (Panel A) | MK-5475 165 ug: Part 1 (Panel A) | MK-5475 240 ug: Part 1 (Panel A) | MK-5475 300 ug: Part 2 Period 1 (Panels B+C) | MK-5475 480 ug: Part 2 Period 1 (Panel D) | Placebo: Part 1 | MK-5475 120 ug: RHC (Panel D) | MK-5475 165 ug: RHC (Panel B) | MK-5475 240 ug: RHC (Panel A) | MK-5475 360 ug: RHC (Panels B+C) | MK-5475 120 ug: FRI (Panels C+D) | MK-5475 165 ug: FRI (Panel B) | MK-5475 240 ug: FRI (Panel A) | MK-5475 360 ug: FRI (Panels B+C) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Back painMusculoskeletal and connective tissue disorders | 0/6 | 0/6 | 2/6 | 0/13 | 0/4 | 0/6 | 3/7 | 1/1 | 4/7 | 3/8 | 0/8 | 0/1 | 0/7 | 0/8 |
| Blood bilirubin increasedInvestigations | 0/6 | 0/6 | 1/6 | 0/13 | 1/4 | 2/6 | 0/7 | 0/1 | 0/7 | 0/8 | 0/8 | 0/1 | 0/7 | 1/8 |
| FatigueGeneral disorders | 0/6 | 0/6 | 0/6 | 0/13 | 0/4 | 0/6 | 2/7 | 0/1 | 0/7 | 0/8 | 0/8 | 0/1 | 0/7 | 0/8 |
| Blood creatinine increasedInvestigations | 0/6 | 0/6 | 0/6 | 0/13 | 1/4 | 1/6 | 0/7 | 0/1 | 0/7 | 0/8 | 0/8 | 0/1 | 0/7 | 0/8 |
| RhinitisInfections and infestations | 0/6 | 0/6 | 0/6 | 0/13 | 0/4 | 1/6 | 0/7 | 0/1 | 0/7 | 0/8 | 0/8 | 0/1 | 0/7 | 0/8 |
| Urinary tract infectionInfections and infestations | 1/6 | 0/6 | 0/6 | 1/13 | 0/4 | 0/6 | 0/7 | 0/1 | 0/7 | 0/8 | 0/8 | 0/1 | 0/7 | 0/8 |
| Alanine aminotransferase increasedInvestigations | 1/6 | 0/6 | 0/6 | 0/13 | 0/4 | 0/6 | 0/7 | 0/1 | 0/7 | 0/8 | 0/8 | 0/1 | 0/7 | 0/8 |
| HyperkalaemiaMetabolism and nutrition disorders | 0/6 | 1/6 | 1/6 | 1/13 | 0/4 | 0/6 | 0/7 | 0/1 | 0/7 | 1/8 | 0/8 | 0/1 | 0/7 | 0/8 |
| DizzinessNervous system disorders | 0/6 | 0/6 | 0/6 | 0/13 | 0/4 | 1/6 | 0/7 | 0/1 | 1/7 | 0/8 | 0/8 | 0/1 | 0/7 | 0/8 |
| Bronchitis chronicRespiratory, thoracic and mediastinal disorders | 0/6 | 0/6 | 0/6 | 0/13 | 0/4 | 1/6 | 0/7 | 0/1 | 0/7 | 0/8 | 0/8 | 0/1 | 0/7 | 0/8 |
| Age, Continuous(Years) | MK-5475 120 ug/MK-5475 165 ug/MK-5475 240 ug/MK-5475 240 ug/MK-5475 240 ug (Panel A) | MK-5475 120 ug/Placebo/MK-5475 240 ug/MK-5475 240 ug/MK-5475 240 ug (Panel A) | MK-5475 120 ug/MK-5475 165 ug/Placebo/MK-5475 240 ug/MK-5475 240 ug (Panel A) | Placebo/MK-5475 165 ug/MK-5475 240 ug/MK-5475 240 ug/MK-5475 240 ug (Panel A) | Placebo/MK-5475 165 ug/MK-5475 240 ug (Panel A) | MK-5475 300 ug/ MK-5475 165 ug/ MK-5475 165 ug (Panel B) | MK-5475 300 ug/ MK-5475 360 ug/ MK-5475 360 ug (Panels B+C) | MK-5475 300 ug/ MK-5475 120 ug/ MK-5475 120 ug (Panel C) | MK-5475 480 ug/ MK-5475 120 ug/ MK-5475 120 ug (Panel D) | MK-5475 480 ug/ MK-5475 120 ug (Panel D) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 53.0 ± 1.4 | 51.0 ± 4.2 | 61.0 ± 4.2 | 61.0 ± NA | 61.0 ± NA | 52.0 ± NA | 48.6 ± 14.4 | 61.3 ± 2.2 | 62.7 ± 5.9 | 69.0 ± NA | 55.8 ± 10.4 |
| Sex: Female, Male(Participants) | MK-5475 120 ug/MK-5475 165 ug/MK-5475 240 ug/MK-5475 240 ug/MK-5475 240 ug (Panel A) | MK-5475 120 ug/Placebo/MK-5475 240 ug/MK-5475 240 ug/MK-5475 240 ug (Panel A) | MK-5475 120 ug/MK-5475 165 ug/Placebo/MK-5475 240 ug/MK-5475 240 ug (Panel A) | Placebo/MK-5475 165 ug/MK-5475 240 ug/MK-5475 240 ug/MK-5475 240 ug (Panel A) | Placebo/MK-5475 165 ug/MK-5475 240 ug (Panel A) | MK-5475 300 ug/ MK-5475 165 ug/ MK-5475 165 ug (Panel B) | MK-5475 300 ug/ MK-5475 360 ug/ MK-5475 360 ug (Panels B+C) | MK-5475 300 ug/ MK-5475 120 ug/ MK-5475 120 ug (Panel C) | MK-5475 480 ug/ MK-5475 120 ug/ MK-5475 120 ug (Panel D) | MK-5475 480 ug/ MK-5475 120 ug (Panel D) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 1 | 2 | 2 | 0 | 1 | 0 | 6 | 3 | 2 | 1 | 18 |
| Male | 1 | 0 | 0 | 1 | 0 | 1 | 2 | 1 | 1 | 0 | 7 |
| Ethnicity (NIH/OMB)(Participants) | MK-5475 120 ug/MK-5475 165 ug/MK-5475 240 ug/MK-5475 240 ug/MK-5475 240 ug (Panel A) | MK-5475 120 ug/Placebo/MK-5475 240 ug/MK-5475 240 ug/MK-5475 240 ug (Panel A) | MK-5475 120 ug/MK-5475 165 ug/Placebo/MK-5475 240 ug/MK-5475 240 ug (Panel A) | Placebo/MK-5475 165 ug/MK-5475 240 ug/MK-5475 240 ug/MK-5475 240 ug (Panel A) | Placebo/MK-5475 165 ug/MK-5475 240 ug (Panel A) | MK-5475 300 ug/ MK-5475 165 ug/ MK-5475 165 ug (Panel B) | MK-5475 300 ug/ MK-5475 360 ug/ MK-5475 360 ug (Panels B+C) | MK-5475 300 ug/ MK-5475 120 ug/ MK-5475 120 ug (Panel C) | MK-5475 480 ug/ MK-5475 120 ug/ MK-5475 120 ug (Panel D) | MK-5475 480 ug/ MK-5475 120 ug (Panel D) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 2 | 2 | 2 | 1 | 1 | 1 | 8 | 4 | 3 | 1 | 25 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | MK-5475 120 ug/MK-5475 165 ug/MK-5475 240 ug/MK-5475 240 ug/MK-5475 240 ug (Panel A) | MK-5475 120 ug/Placebo/MK-5475 240 ug/MK-5475 240 ug/MK-5475 240 ug (Panel A) | MK-5475 120 ug/MK-5475 165 ug/Placebo/MK-5475 240 ug/MK-5475 240 ug (Panel A) | Placebo/MK-5475 165 ug/MK-5475 240 ug/MK-5475 240 ug/MK-5475 240 ug (Panel A) | Placebo/MK-5475 165 ug/MK-5475 240 ug (Panel A) | MK-5475 300 ug/ MK-5475 165 ug/ MK-5475 165 ug (Panel B) | MK-5475 300 ug/ MK-5475 360 ug/ MK-5475 360 ug (Panels B+C) | MK-5475 300 ug/ MK-5475 120 ug/ MK-5475 120 ug (Panel C) | MK-5475 480 ug/ MK-5475 120 ug/ MK-5475 120 ug (Panel D) | MK-5475 480 ug/ MK-5475 120 ug (Panel D) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| White | 2 | 2 | 2 | 1 | 1 | 1 | 8 | 4 | 3 | 1 | 25 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · externaldatasharing-msd.com
Ran from Jan 2019 to primary completion in Dec 2020, 22 months.
Results were first posted in Feb 2022, 1 year 2 months after primary completion.
Of 34 industry-sponsored phase 1 interventional studies under Pulmonary Arterial Hypertension, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 17. This study's 22 months is above that.
Counting every sponsor, half of 45 studies reached it within 9 months; a quarter within 2 and three quarters within 22.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Frespaciguat
Pulmonary Arterial Hypertension →